Related Experiment Video
Updated: Jul 7, 2026
05:22
Iris Fixation via External Pentagram Suturing
Published on: May 5, 2022
[Basiliximab following penetrating risk-keratoplasty--a prospective randomized pilot study]
F Birnbaum1, T Jehle, J Schwartzkopff
1Augenklinik, Universitätsklinik Freiburg. florian.birnbaum@uniklinik-freiburg.de
Klinische Monatsblatter Fur Augenheilkunde
|February 1, 2008
Summary
Basiliximab shows fewer immune reactions after risk keratoplasty than cyclosporin A (CSA), but is less effective. Basiliximab offers a better safety profile, making it a favorable option despite lower efficacy in preventing immune reactions.
Area of Science:
- Ophthalmology
- Immunology
- Transplantation
Background:
- Current systemic immunosuppressants for risk keratoplasty include cyclosporin A (CSA) and mycophenolate mofetil (MMF).
- Basiliximab, an interleukin 2-receptor antibody, inhibits T-cell proliferation and is approved for kidney transplant patients.
Purpose of the Study:
- To evaluate the efficacy and safety of basiliximab in patients undergoing penetrating risk keratoplasty.
Main Methods:
- A prospective study involving 20 patients undergoing risk keratoplasty.
- Basiliximab group (n=10) received basiliximab post-surgery.
- Control group (n=10) received oral CSA, monitored for blood-trough levels.
Main Results:
- Basiliximab group: 4 corneal immune reactions (2 irreversible) with no observed side effects.
- CSA group: 2 immune reactions (1 irreversible); 2 patients discontinued CSA due to side effects.
- Mean follow-up was 477 days.
Conclusions:
- Basiliximab demonstrates a more favorable side effect profile compared to CSA after risk keratoplasty.
- While less effective in preventing immune reactions than CSA, basiliximab's safety is advantageous.